Avian influenza—commonly known as bird flu—is a viral infection that primarily affects birds but can occasionally infect humans, sometimes with severe consequences. Highly pathogenic strains such as H5N1 and H7N9 have caused human infections with high mortality rates, raising concerns about pandemic potential. Vaccination of poultry is a key control measure, and human vaccines are stockpiled for pandemic preparedness. As avian influenza outbreaks increase globally and as pandemic concerns persist, the Avian Influenza Vaccine Market is expanding.

The Avian Influenza Vaccine Market is driven by several factors, including rising avian influenza outbreaks, pandemic preparedness programmes, growing poultry production, and government vaccination mandates. The market encompasses poultry vaccines and human vaccines. Poultry vaccines represent the largest segment, driven by the need to control outbreaks in commercial flocks. Human vaccines are stockpiled by governments for pandemic preparedness.

Technological innovation is advancing vaccine development. Recombinant vaccines offer improved safety and efficacy. mRNA platforms enable rapid response to emerging strains. Adjuvants improve immune response and dose-sparing. Key players include Zoetis, Merck Animal Health, Ceva Santé Animale, and human vaccine manufacturers such as Seqirus and Sanofi. As avian influenza outbreaks increase and as pandemic preparedness remains a priority, the Avian Influenza Vaccine Market is positioned for sustained growth.

People Also Ask

• What is avian influenza?
  Avian influenza, or bird flu, is a viral infection that primarily affects birds but can occasionally infect humans, sometimes severely.

• Why is the avian influenza vaccine market growing?
  Growth is driven by rising outbreaks, pandemic preparedness programmes, expanding poultry production, and government vaccination mandates.

Tags: #AvianInfluenza #BirdFlu #Vaccines #PandemicPreparedness #PoultryHealth #PublicHealth